Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
Shasta County Jail partners with Mediko to launch medication-assisted treatment for substance use disorders and prepares for California's CalAIM reentry initiative.
DEA files notice of intent to classify 7-OH and synthetic compounds as Schedule I drugs, targeting products currently sold over the counter in Hawaii with no age restrictions.
Scienture Holdings begins shipping REZENOPY, a 10mg naloxone nasal spray—the highest FDA-approved dose—bringing a new overdose reversal option as fentanyl deaths decline nationwide.
The Department of Veterans Affairs is expanding FDA-authorized virtual reality therapy to treat chronic pain in veterans, offering an eight-week home-based program that reduces reliance on opioids.
DEA announces emergency Schedule I scheduling for investigational opioid compounds SR17018, SR-14968, R-6890, and 5,6-dichloro-brorphine, raising concerns about impact on pain medication research.
Study in Drug and Alcohol Dependence finds standard methadone and buprenorphine doses often inadequate for heavy fentanyl dependence, raising treatment retention concerns.
Wisconsin reports 1,185 drug overdose deaths in 2024, a 33% decline from 2022 peak, as naloxone distribution and medication-assisted treatment expansion show measurable results.
FDA cracks down on illegal online ketamine market with 14 warning letters to websites selling non-approved ketamine products for depression and addiction treatment.
Phase 3 trial shows Eli Lilly's oral GLP-1 drug orforglipron delivers superior blood sugar control and weight loss compared to oral semaglutide.